Recently, 2021 China Healthcare Summit of Entrepreneurs, Scientists and Investor hosted by the China Pharmaceutical Enterprises Association, China Medical Biotech Association and the general office of the Central Committee of the China peasants and Workers Democratic Party was grandly held online. Hrain was announced into the list of 2021 Top 100 Chinese Pharmaceutical Innovation seed Enterprises.

The list was jointly launched by the organizers and the world-renowned data company Kerui Weian. Through the three dimensions of innovation foundation, innovation process and innovation achievements, Select the number of authorized patents, total amount of patent introduction, number of clinical trials in research, and number of approved and listed new drugs as the main evaluation systems. Hrain successfully entered the list based on its outstanding achievements in the field of new drug research and development.
 

Since its establishment, Hrain has been approved with four Clinical Trial Permission of class 1.1 new drugs, all of them have been entered clinical trials. At present, Hrain has obtained nearly 100 applied invention patents, and nearly 20 authorized invention patents. Meanwhile Hrain successively won a number of authoritative innovation awards and qualification certification. Whose solid innovation and R&D strength, industry recognition, encouragement and support from the nation have strengthened the confidence of Hrain to unswervingly follow the independent R&D route and carry out industrial transformation.